Kymera Therapeutics, Inc.

NASDAQ•KYMR

CEO: Dr. Bruce L. Booth DPHIL, Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2020-08-21

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Contact Information

200 Arsenal Yards Boulevard, Suite 230, Watertown, MA, 02472, United States

857-285-5300

www.kymeratx.com

Market Cap

$6.97B

P/E (TTM)

-23.1

18.3

Dividend Yield

52W High

$103.00

52W Low

$19.45

52W Range

79%

Rank61Top 91.5%

2.0

F-Score

Modified Piotroski Analysis

Based on 7-year fundamentals

Weak • 2 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2019-2025

Financial Dashboard

Q4 2025 Data

Revenue

$2.86M+0.00%

4-Quarter Trend

EPS

-$0.98+0.00%

4-Quarter Trend

FCF

-$66.85M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Loss Widens Net loss $311.4M USD in 2025, up $87.5M, driven by increased R&D investment and clinical costs.

R&D Spending Rises R&D expenses $316.6M USD in 2025, up $76.3M, primarily due to increased STAT6 program costs.

Cash Position Solid Total cash and marketable securities $848.3M USD end of 2025; sufficient funding projected into 2029.

Pipeline Progress Continues KT-621 Phase 2b trials active; Sanofi advancing KT-485 into clinical testing in 2026 following program prioritization.

Risk Factors

Funding Needs Remain High Substantial additional funding required; failure to raise capital forces delays or discontinuation of development programs.

Clinical Stage Uncertainty Early clinical stage status presents inherent risks; future viability difficult to assess without successful trial outcomes.

Reliance on Third Parties Heavy reliance on external CROs and CMOs for clinical trials and manufacturing supply chain execution.

IP Protection Challenges Success depends on securing broad patent protection; litigation risk could impair competitive advantage and commercialization.

Outlook

Advance Critical Inflection Points Plan to advance existing clinical and preclinical programs through critical inflection points to de-risk molecules approach.

Expand Therapeutic Pipeline Intend to expand therapeutic pipeline by identifying high-value targets well-suited for TPD approaches moving forward.

Build Integrated Capabilities Will continue building organizational capabilities to advance goal of becoming a fully integrated biopharmaceutical company.

Strategic Collaboration Leverage Continue considering synergistic collaboration opportunities to further goal of delivering transformative therapies broadly.

Peer Comparison

Revenue (TTM)

ACAD

$1.07B

+11.9%

ZLAB

$460.16M

+15.3%

SLNO

$190.41M

+0.0%

Gross Margin (Latest Quarter)

KYMR

2763.6%

-2680.7pp

CRNX

111.8%

+0.0pp

SLNO

99.1%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
KYMR	$6.97B	-23.1	-29.1%	4.7%
ACLX	$6.71B	-28.2	-55.4%	15.9%
PRAX	$6.56B	-23.0	-58.7%	0.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-49.4%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026

EPS:-$0.87

Revenue:$8.01M

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data